Basic Information
| LncRNA/CircRNA Name | LMCD1-AS1 |
| Synonyms | NA |
| Region | GRCh38_3:7952805-8611924 |
| Ensemble | ENSG00000227110 |
| Refseq | NR_033378 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | aspirin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | HepG2 and Huh-7 cell lines, liver tumour tissues and para-tumour tissues |
| Expression Pattern | down-regulated |
| Function Description | In xenograft mice, aspirin was capable of targeting P4HA2 to decrease collagen deposition, resulting in the inhibition of liver tumour growth. TCGA database analysis revealed the close association between a higher P4HA2 concentration in HCC patients and shorter overall survival or a higher cancer stage and the pathological grade. Mechanistically, NF-?B can bind to the promoter of P4HA2 to activate its transcription. Moreover, lncRNA LMCD1-AS1 functions as a molecular sponge of let-7g to post-transcriptionally induce the target gene of let-7g, namely, P4HA2 |
| Pubmed ID | 31278071 |
| Year | 2019 |
| Title | Aspirin targets P4HA2 through inhibiting NF-?B and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma |
External Links
| Links for LMCD1-AS1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |